Nothing Special   »   [go: up one dir, main page]

SG10201408165WA - Compositions and methods related to mrna translational enhancer elements - Google Patents

Compositions and methods related to mrna translational enhancer elements

Info

Publication number
SG10201408165WA
SG10201408165WA SG10201408165WA SG10201408165WA SG10201408165WA SG 10201408165W A SG10201408165W A SG 10201408165WA SG 10201408165W A SG10201408165W A SG 10201408165WA SG 10201408165W A SG10201408165W A SG 10201408165WA SG 10201408165W A SG10201408165W A SG 10201408165WA
Authority
SG
Singapore
Prior art keywords
translational enhancer
compositions
enhancer elements
methods related
mrna
Prior art date
Application number
SG10201408165WA
Inventor
Vincent P Mauro
Gerald M Edelman
Wei Zhou
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG10201408165WA publication Critical patent/SG10201408165WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSITIONS AND METHODS RELATED TO MRNA TRANSLATIONAL ENHANCER ELEMENTS Abstract 5 Provided are mRNA translationa! enhancer elements (TEEs), e.g., SEQ ID NOs: 1- 35. Also provided are translational enhancer polynucleotides that comprise one or more of the specific TEEs exemplified herein or their variants, homologs or functional derivatives. Further provided are expression vectors comprising such TEEs or translational enhancer 10 polynucleotides, as well as host cells and expression systems that harbor such vectors. Fig. 1 35
SG10201408165WA 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements SG10201408165WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US744007P 2007-12-11 2007-12-11

Publications (1)

Publication Number Publication Date
SG10201408165WA true SG10201408165WA (en) 2015-01-29

Family

ID=40386467

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201408162PA SG10201408162PA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG10201408165WA SG10201408165WA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG10201408164XA SG10201408164XA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG2013017025A SG188866A1 (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201408162PA SG10201408162PA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201408164XA SG10201408164XA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG2013017025A SG188866A1 (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Country Status (8)

Country Link
US (2) US8785611B2 (en)
EP (5) EP2584038B1 (en)
JP (3) JP5474816B2 (en)
CN (2) CN103911378A (en)
AU (1) AU2008335723C1 (en)
CA (2) CA2904904A1 (en)
SG (4) SG10201408162PA (en)
WO (1) WO2009075886A1 (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130230884A1 (en) * 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP2013543381A (en) 2010-10-01 2013-12-05 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acids and methods of use
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
CN104114572A (en) 2011-12-16 2014-10-22 现代治疗公司 Modified nucleoside, nucleotide, and nucleic acid compositions
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2868438A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
ES2921623T3 (en) 2012-11-26 2022-08-30 Modernatx Inc terminally modified RNA
EP2946014A2 (en) 2013-01-17 2015-11-25 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
CN111621524A (en) * 2013-11-12 2020-09-04 Vrije布鲁塞尔大学 RNA transcription vector and use thereof
JP2017524357A (en) 2014-07-16 2017-08-31 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chimeric polynucleotide
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3041948B1 (en) 2014-11-10 2019-01-09 Modernatx, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
PT3350157T (en) 2015-09-17 2022-03-18 Modernatx Inc Compounds and compositions for intracellular delivery of therapeutic agents
US12109274B2 (en) 2015-09-17 2024-10-08 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066793A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
EP4036079A3 (en) 2015-12-22 2022-09-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3394093B1 (en) 2015-12-23 2022-01-26 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
MA43587A (en) 2016-01-10 2018-11-14 Modernatx Inc THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
KR102469450B1 (en) 2016-05-18 2022-11-22 모더나티엑스, 인크. Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
CN116726203A (en) 2016-05-18 2023-09-12 莫得纳特斯公司 Combination of MRNA encoding immunomodulatory polypeptides and uses thereof
EP3458081A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
WO2017201328A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP7167049B2 (en) 2017-03-15 2022-11-08 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of therapeutic agents
EP3595727A1 (en) 2017-03-15 2020-01-22 ModernaTX, Inc. Lipid nanoparticle formulation
CA3063723A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP3625345B1 (en) 2017-05-18 2023-05-24 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3638678A1 (en) 2017-06-14 2020-04-22 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20200362382A1 (en) 2017-08-18 2020-11-19 Modernatx, Inc. Methods of preparing modified rna
MX2020002348A (en) 2017-08-31 2020-10-08 Modernatx Inc Methods of making lipid nanoparticles.
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
US20220409536A1 (en) 2018-09-19 2022-12-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (en) 2018-09-20 2021-08-17 摩登纳特斯有限公司 Preparation of lipid nanoparticles and methods of administration thereof
JP2022519557A (en) 2019-01-31 2022-03-24 モデルナティエックス インコーポレイテッド Method for preparing lipid nanoparticles
AU2020214425A1 (en) 2019-01-31 2021-08-19 Modernatx, Inc. Vortex mixers and associated methods, systems, and apparatuses thereof
US20220251577A1 (en) 2019-06-24 2022-08-11 Modernatx, Inc. Endonuclease-resistant messenger rna and uses thereof
WO2020263985A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
BR112022014837A2 (en) 2020-01-28 2022-09-27 Modernatx Inc RNA VACCINES AGAINST CORONA VIRUS
IL295377A (en) 2020-02-07 2022-10-01 Modernatx Inc Sars-cov-2 mrna domain vaccines
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
CA3178455A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
JP2023532707A (en) 2020-06-30 2023-07-31 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド Lipid compounds and lipid nanoparticle compositions
CN116710079A (en) 2020-07-24 2023-09-05 斯特兰德生物科技公司 Lipid nanoparticles comprising modified nucleotides
JP2023537887A (en) 2020-08-20 2023-09-06 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド Lipid compounds and lipid nanoparticle compositions
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
TW202241931A (en) 2021-01-08 2022-11-01 美商斯特蘭德治療股份有限公司 Expression constructs and uses thereof
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
EP4308156A1 (en) 2021-03-15 2024-01-24 ModernaTX, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
JP2024512780A (en) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド Method for identification and ratio determination of RNA species in multivalent RNA compositions
US20240216500A1 (en) 2021-04-13 2024-07-04 Modernatx, Inc. Respiratory virus combination vaccines
WO2022221440A1 (en) 2021-04-14 2022-10-20 Modernatx, Inc. Influenza-coronavirus combination vaccines
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
CA3211623A1 (en) 2021-05-24 2022-12-01 Bo YING Lipid compounds and lipid nanoparticle compositions
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
TW202321446A (en) 2021-08-13 2023-06-01 美商現代公司 Multicolumn chromatography mrna purification
AR127312A1 (en) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
WO2023056917A1 (en) 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
EP4419081A1 (en) 2021-10-22 2024-08-28 Sail Biomedicines, Inc. Mrna vaccine composition
WO2023076658A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Mass spectrometry of mrna
WO2023081311A1 (en) 2021-11-05 2023-05-11 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
EP4444345A2 (en) 2021-12-08 2024-10-16 ModernaTX, Inc. Herpes simplex virus mrna vaccines
CA3241014A1 (en) 2021-12-20 2023-06-29 Munir MOSAHEB Mrna therapeutic compositions
CA3241492A1 (en) 2021-12-23 2023-06-29 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
CN118647718A (en) 2022-02-03 2024-09-13 摩登纳特斯有限公司 Continuous precipitation for mRNA purification
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
TW202424187A (en) 2022-10-27 2024-06-16 美商輝瑞大藥廠 Rna molecules
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024097874A1 (en) 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024151811A1 (en) 2023-01-11 2024-07-18 Modernatx, Inc. Personalized cancer vaccines
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
WO2024191860A2 (en) 2023-03-10 2024-09-19 Modernatx, Inc. Nucleic acid influenza vaccines and respiratory virus combination vaccines
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024216162A1 (en) 2023-04-12 2024-10-17 Strand Therapeutics Inc. Synthetic circuits and uses thereof
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6116184A (en) 1996-05-21 2000-09-12 Symetrix Corporation Method and apparatus for misted liquid source deposition of thin film with reduced mist particle size
US6653132B1 (en) * 1997-02-25 2003-11-25 Qbi Enterprises, Ltd. IRES sequences with high translational efficiency and expression vectors containing the sequence
US6310197B1 (en) * 1997-11-12 2001-10-30 The Brigham And Women's Hospital, Inc. Translation enhancer element of the human amyloid precursor protein gene
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
AU775750B2 (en) * 1999-01-26 2004-08-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Internal ribosome entry site (IRES), vector containing same and uses thereof
BR0107930A (en) * 2000-01-28 2004-06-15 Scripps Research Inst Methods for identifying synthetic transcriptional and translational regulatory elements, and compositions relating to them
WO2001071036A2 (en) * 2000-03-17 2001-09-27 Gene Logic, Inc. Methods of preparing amplified nucleic acid molecules
WO2002019968A2 (en) * 2000-09-08 2002-03-14 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
EP1934329B1 (en) 2005-08-24 2016-11-02 The Scripps Research Institute Translation enhancer-element dependent vector systems

Also Published As

Publication number Publication date
CN103911378A (en) 2014-07-09
CN101939428B (en) 2014-05-07
JP2011505831A (en) 2011-03-03
CN101939428A (en) 2011-01-05
WO2009075886A8 (en) 2010-11-11
AU2008335723C1 (en) 2013-05-30
SG10201408162PA (en) 2015-01-29
EP2231859A1 (en) 2010-09-29
JP5474816B2 (en) 2014-04-16
AU2008335723B2 (en) 2012-12-13
EP2584038B1 (en) 2014-06-25
US8785611B2 (en) 2014-07-22
CA2708766C (en) 2016-02-02
US20130177581A1 (en) 2013-07-11
EP2231859B1 (en) 2013-01-23
EP2610340B1 (en) 2014-10-01
EP2527439A3 (en) 2012-12-05
EP2610340A1 (en) 2013-07-03
SG10201408164XA (en) 2015-01-29
WO2009075886A1 (en) 2009-06-18
JP5873511B2 (en) 2016-03-01
EP2527439A2 (en) 2012-11-28
JP2016104027A (en) 2016-06-09
EP2610341A1 (en) 2013-07-03
EP2527439B1 (en) 2014-03-26
AU2008335723A1 (en) 2009-06-18
CA2708766A1 (en) 2009-06-18
EP2610341B1 (en) 2014-09-17
US20090226470A1 (en) 2009-09-10
SG188866A1 (en) 2013-04-30
EP2584038A1 (en) 2013-04-24
JP2014113163A (en) 2014-06-26
CA2904904A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
SG10201408165WA (en) Compositions and methods related to mrna translational enhancer elements
MX2010004674A (en) Alpha-amylase variants with altered properties.
IN2012DN00403A (en)
MX2009009948A (en) Pyridazinone derivatives useful as glucan synthase inhibitors.
MX2011006645A (en) Polypeptides with xylanase activity.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MY158106A (en) Inhibitors of e1 activating enzymes
PT1991680E (en) System for the expression of orthogonal translation components in eubacterial host cells
MX2020005458A (en) Alpha-amylase variants and polynucleotides encoding same.
MX2010006933A (en) Compositions and methods for reducing or preventing water loss from the skin.
MY147970A (en) 2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
WO2008104979A3 (en) Nuclear targeting sequences
MX2010003328A (en) Cell-permeabilising peptides and polypeptides for microbial cells.
MY159575A (en) Dihydroorotate dehydrogenase inhibitors
MY155242A (en) Antireflective coating compositions
MX2009008000A (en) Variant buttiauxella sp. phytases having altered properties.
MX2010000593A (en) Increasing plant vigor.
WO2008109142A3 (en) Pirna and uses related thereto
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
BRPI1015043A2 (en) diazahomoadamantane derivatives and methods of use thereof
WO2011140527A3 (en) Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
MX2013003571A (en) Styrenic (meth)acrylic oligomers.
UA100127C2 (en) Peptide cdh3 and drug containing it
MX2009010174A (en) Azaadamantane ester and carbamate derivatives and methods of use thereof.